Key facts
- It has raised $1.4M; the latest was Accelerator/Incubator in Jan 2026.
- Notable investors include Plug and Play Tech Center, Seeds of Bravery, Caelestinus, 28DIGITAL, Challenger Accelerator — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for CheckEye
- ·The full record, as it builds
Funding rounds
No funding rounds for CheckEye are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CheckEye
Developer of an AI-driven platform designed for chronic disease screening using retinal imaging. The company's platform uses artificial intelligence to enable early detection of chronic diseases through analysis of eye fundus images and utilizes cloud-based machine learning algorithms to diagnose diabetic retinopathy and other chronic diseases, enabling clients to implement accessible and cost-effective chronic disease screening programs.
- Sector
- Healthcare
- HQ
- Kyiv, Ukraine
- Founded
- 2022
- Employees
- 17
- Website
- check-eye.com/
- Ownership
- Privately Held (backing)
CheckEye doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CheckEye shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CheckEye in its N-PORT filings yet. We sweep new filings monthly.